Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?

Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial.

We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at fool.com →

More in Finance & Markets

More from Wednesday 21 October →